Amphastar Pharmaceuticals (NASDAQ:AMPH) EVP Rong Zhou Sells 10,000 Shares of Stock

Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) EVP Rong Zhou sold 10,000 shares of the business’s stock in a transaction dated Wednesday, September 16th. The shares were sold at an average price of $23.94, for a total transaction of $239,400.00. Following the transaction, the executive vice president directly owned 169,203 shares in the company, valued at approximately $4,050,719.82. The trade was a 5.58% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink.

Rong Zhou also recently made the following trade(s):

• On Wednesday, September 2nd, Rong Zhou sold 3,187 shares of Amphastar Pharmaceuticals stock. The shares were sold at an average price of $23.63, for a total transaction of $75,308.81.

Amphastar Pharmaceuticals Trading Down 0.5%

Shares of Amphastar Pharmaceuticals stock traded down $0.13 during mid-day trading on Thursday, hitting $23.82. The stock had a trading volume of 465,639 shares, compared to its average volume of 514,906. The firm has a 50-day moving average of $21.10 and a two-hundred day moving average of $20.30. The firm has a market cap of $1.01 billion, a P/E ratio of 14.09, a price-to-earnings-growth ratio of 4.55 and a beta of 0.92. The company has a quick ratio of 1.71, a current ratio of 2.40 and a debt-to-equity ratio of 0.79. Amphastar Pharmaceuticals, Inc. has a 12-month low of $16.65 and a 12-month high of $29.52.

Amphastar Pharmaceuticals (NASDAQ:AMPH) last released its quarterly earnings results on Thursday, August 6th. The company reported $0.91 EPS for the quarter, beating the consensus estimate of $0.62 by $0.29. The firm had revenue of $183.90 million for the quarter, compared to analyst estimates of $179.92 million. Amphastar Pharmaceuticals had a net margin of 10.76% and a return on equity of 14.98%. Sell-side analysts forecast that Amphastar Pharmaceuticals, Inc. will post 2.46 earnings per share for the current year.

Wall Street Analyst Weigh In

AMPH has been the subject of a number of recent analyst reports. Weiss Ratings reiterated a “sell (d+)” rating on shares of Amphastar Pharmaceuticals in a research report on Wednesday, July 8th. Barclays increased their price objective on shares of Amphastar Pharmaceuticals from $20.00 to $23.00 and gave the stock an “equal weight” rating in a research report on Tuesday, August 18th. Piper Sandler cut their target price on Amphastar Pharmaceuticals from $21.00 to $20.00 and set a “neutral” rating on the stock in a research report on Friday, August 7th. Zacks Research upgraded Amphastar Pharmaceuticals from a “strong sell” rating to a “hold” rating in a research note on Tuesday, July 21st. Finally, Wall Street Zen lowered Amphastar Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research report on Saturday, September 12th. Six research analysts have rated the stock with a Hold rating and two have given a Sell rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Reduce” and a consensus target price of $22.50.

Institutional Investors Weigh In On Amphastar Pharmaceuticals

Several large investors have recently bought and sold shares of the stock. Quantbot Technologies LP acquired a new stake in Amphastar Pharmaceuticals in the second quarter valued at approximately $39,000. TD Private Client Wealth LLC raised its holdings in shares of Amphastar Pharmaceuticals by 410.1% in the 4th quarter. TD Private Client Wealth LLC now owns 2,418 shares of the company’s stock valued at $65,000 after purchasing an additional 1,944 shares in the last quarter. Hantz Financial Services Inc. raised its holdings in shares of Amphastar Pharmaceuticals by 43.6% in the 4th quarter. Hantz Financial Services Inc. now owns 4,484 shares of the company’s stock valued at $120,000 after purchasing an additional 1,362 shares in the last quarter. State of Wyoming purchased a new stake in shares of Amphastar Pharmaceuticals during the 2nd quarter worth $142,000. Finally, ProShare Advisors LLC grew its stake in shares of Amphastar Pharmaceuticals by 5.3% during the fourth quarter. ProShare Advisors LLC now owns 9,083 shares of the company’s stock worth $243,000 after purchasing an additional 457 shares in the last quarter. Hedge funds and other institutional investors own 65.09% of the company’s stock.

About Amphastar Pharmaceuticals

Amphastar Pharmaceuticals, Inc is a biopharmaceutical company that develops, manufactures and markets injectable, inhaled and intranasal products. The company focuses on complex and technically challenging medicines, including products for diabetes, emergency medicine, respiratory conditions and other specialty-care applications.

Its marketed products include glucagon for treating severe hypoglycemia, BAQSIMI nasal glucagon, Primatene MIST for temporary relief of mild intermittent asthma symptoms, naloxone products for opioid overdose emergencies, and enoxaparin sodium injection, an anticoagulant.